Simcere Pharmaceutical Group Limited (2096.HK)

HKD 8.99

(2.63%)

Net Debt Summary of Simcere Pharmaceutical Group Limited

Simcere Pharmaceutical Group Limited's latest annual net debt in 2023 was -577.93 Million CNY , down -283.11% from previous year.
Simcere Pharmaceutical Group Limited's latest quarterly net debt in 2024 Q1 was -1.75 Billion CNY , down -203.14% from previous quarter.
Simcere Pharmaceutical Group Limited reported annual net debt of -150.85 Million CNY in 2022, down -122.76% from previous year.
Simcere Pharmaceutical Group Limited reported annual net debt of 662.74 Million CNY in 2021, up 2125.69% from previous year.
Simcere Pharmaceutical Group Limited reported quarterly net debt of -1.75 Billion CNY for 2024 Q2, up 10.21% from previous quarter.
Simcere Pharmaceutical Group Limited reported quarterly net debt of -657.78 Million CNY for 2023 Q3, up 49.0% from previous quarter.

Annual Net Debt Chart of Simcere Pharmaceutical Group Limited (2023 - 2012)

Historical Annual Net Debt of Simcere Pharmaceutical Group Limited (2023 - 2012)

Year	Net Debt	Net Debt Growth
2023	-577.93 Million CNY	-283.11%
2022	-150.85 Million CNY	-122.76%
2021	662.74 Million CNY	2125.69%
2020	29.77 Million CNY	-98.85%
2019	2.58 Billion CNY	128.82%
2018	1.13 Billion CNY	51.7%
2017	745.02 Million CNY	0.0%
2012	-178.16 Million CNY	0.0%

Year	Net Debt	Net Debt Growth
2024 Q1	-1.75 Billion CNY	-203.14%
2024 Q2	-1.75 Billion CNY	10.21%
2023 Q3	-657.78 Million CNY	49.0%
2023 Q4	-577.93 Million CNY	12.14%
2023 FY	-577.93 Million CNY	-283.11%
2023 Q1	-1.36 Billion CNY	-806.84%
2023 Q2	-1.28 Billion CNY	5.71%
2022 FY	-150.85 Million CNY	-122.76%
2022 Q4	-150.85 Million CNY	28.27%
2022 Q3	-210.32 Million CNY	40.01%
2022 Q2	-350.61 Million CNY	12.75%
2022 Q1	-401.84 Million CNY	-160.63%
2021 Q3	631.18 Million CNY	-24.73%
2021 Q2	838.59 Million CNY	4.71%
2021 Q1	800.85 Million CNY	2589.52%
2021 FY	662.74 Million CNY	2125.69%
2021 Q4	662.74 Million CNY	5.0%
2020 Q4	29.77 Million CNY	457.85%
2020 Q2	3.14 Billion CNY	1.22%
2020 Q1	3.1 Billion CNY	20.03%
2020 FY	29.77 Million CNY	-98.85%
2020 Q3	-8.32 Million CNY	-100.26%
2019 Q4	2.58 Billion CNY	1.02%
2019 Q1	1.45 Billion CNY	0.0%
2019 FY	2.58 Billion CNY	128.82%
2019 Q3	2.55 Billion CNY	0.0%
2018 FY	1.13 Billion CNY	51.7%
2017 FY	745.02 Million CNY	0.0%
2013 Q1	404.85 Million CNY	327.24%
2013 Q3	35.12 Million CNY	-65.19%
2013 Q2	100.9 Million CNY	-75.08%
2012 Q4	-178.16 Million CNY	-16.96%
2012 FY	-178.16 Million CNY	0.0%
2012 Q1	-422.9 Million CNY	0.0%
2012 Q2	-352.26 Million CNY	16.7%
2012 Q3	-152.33 Million CNY	56.76%

Peer Net Debt Comparison of Simcere Pharmaceutical Group Limited

Name	Net Debt	Net Debt Difference
Uni-Bio Science Group Limited	-76.36 Million HKD	-656.77%
CK Life Sciences Int'l., (Holdings) Inc.	5.26 Billion HKD	110.973%